Tagrisso (Osimertinib) 80mg*30 | AstraZeneca UK Originator | GLT

Generic Information: Tagrisso (Osimertinib) 80mg — United Kingdom

Tagrisso is the originator brand of osimertinib, developed by AstraZeneca and first approved by the US FDA in 2015 under accelerated approval for T790M-positive NSCLC, followed by full approvals for first-line and adjuvant use. This listing is the UK-sourced presentation: 80 mg film-coated tablets in a 30-tablet pack. As the reference product against which all generics are benchmarked, Tagrisso carries the most extensive clinical dataset of any osimertinib product, spanning the AURA, FLAURA and ADAURA trial programmes.

AstraZeneca manufactures Tagrisso's active ingredient and finished product at facilities in the United Kingdom and Sweden, with regional packaging operations elsewhere. Buyers looking for the originator should confirm the pack's market of origin, as this affects labelling and import requirements.

What Is Tagrisso Used For?

Tagrisso treats EGFR mutation-positive non-small cell lung cancer across multiple stages: as first-line therapy for advanced disease, as adjuvant therapy after complete resection of early-stage EGFR-mutant NSCLC, and for T790M-positive disease that has progressed on an earlier EGFR TKI. Its strong central nervous system penetration makes it a preferred option when brain metastases are present.

How Does Tagrisso Work?

Osimertinib is an irreversible, mutant-selective EGFR tyrosine kinase inhibitor. It binds covalently to EGFR bearing exon 19 deletions, L858R substitutions or the T790M mutation at concentrations roughly nine-fold lower than those needed to inhibit wild-type EGFR. This selectivity underlies both its efficacy and its relatively manageable skin and gastrointestinal toxicity profile.

Indications

• First-line treatment of metastatic EGFR-mutant NSCLC (exon 19 del / L858R).
• Adjuvant treatment after tumour resection in EGFR-mutant NSCLC.
• T790M-positive NSCLC after progression on prior EGFR-TKI therapy.
• Maintenance in unresectable stage III EGFR-mutant NSCLC after chemoradiation (region-dependent).

Dosage and Administration

The recommended dose is 80 mg once daily, swallowed whole, with or without food. Missed doses within 12 hours can be taken when remembered; otherwise the dose is skipped. For patients who cannot swallow, the tablet may be dispersed in non-carbonated water. Dose reduction to 40 mg daily is an option for toxicity management.

Side Effects

Common side effects include diarrhoea, rash, dry skin, paronychia, stomatitis, fatigue and decreased appetite. Clinically important risks include interstitial lung disease/pneumonitis, QT prolongation and cardiomyopathy, which require monitoring. Patients should report new cough, breathlessness or palpitations promptly.

Storage

Store Tagrisso at or below 30°C in the original packaging, protected from moisture. Keep out of the sight and reach of children.

Why Choose the GLT?

GLT can source the originator Tagrisso and its regional presentations for buyers who specifically require the AstraZeneca brand, alongside documentation for import and compliance. While the UK and US list prices of Tagrisso are high, GLT helps institutions and patients identify the most cost-effective compliant supply route and provides clear, responsive ordering support.

How to Order Tagrisso from GLT

Contact GLT on WhatsApp at +86 15234153837 or email [email protected] to inquire about Tagrisso 80 mg (30 tablets). Specify your required market presentation (UK or China), quantity and destination. We confirm pricing, batch origin and shipping documentation before dispatch.

FAQ

Is Tagrisso the original osimertinib? Yes, Tagrisso is the originator brand developed by AstraZeneca; all other osimertinib products are generics of it.

What is the difference between UK and China Tagrisso? The active ingredient and dose are identical; the difference is the market packaging and labelling, which affects import documentation.

Where can I buy Tagrisso online? GLT can arrange supply of Tagrisso for international buyers; reach us on WhatsApp or email for availability.